Wide variations in appropriateness of rectal cancer surgery across England

June 04, 2008

A substantial proportion of rectal cancer patients are receiving inappropriate surgical care, because of wide variations in practice across England, reveals research published ahead of print in the journal Gut.

The variation was not associated with how far the disease had advanced or how old the patient was, the data showed.

The findings are based on information obtained from the eight cancer registries in England, which track the progress of all patients with cancer, and NHS hospital data on admissions and treatment between1998?.

During this period, 58 290 patients were diagnosed with rectal cancer in England, of whom 31 223 underwent major abdominal surgery in 153 hospitals to treat their disease.

Around 13 000 people are diagnosed with rectal cancer every year in the UK, and the disease has an annual death toll of around 5000.

There are several different surgical approaches to rectal cancer treatment, the most common of which used to be abdominoperineal excision, or APE for short.

This involves the removal of the anal sphincter, necessitating the permanent use of a colostomy bag. But mounting evidence indicates that although APE is unavoidable in some patients, it should not be the preferred procedure for most of them.

Furthermore, the evidence shows that APE is also associated with higher rates of recurrence and poorer survival than a procedure called anterior resection, or AR for short.

The Department of Health has published guidance, encouraging surgeons, wherever possible, to use alternative methods and adopt AR, which obviates the need for a colostomy bag.

The figures showed that many surgeons had taken the evidence on board, because rates of APE fell from almost one in three procedures (30.5%) in 1998 to almost one in four (23%) in 2004.

But there were wide variations in the use of APE among different cancer networks, individual surgeons as well as hospital trusts, where rates varied from 8.5% to almost 53%.

In 1998, one in three patients were also operated on a by a surgeon who performed fewer than seven rectal cancer procedures in a year. By 2004, this had fallen to around one in four (26.5%).

Patients treated by a specialist surgeon undertaking seven or more cases of rectal cancer a year were 23% less likely to be treated with APE than those with less experience.

The figures also revealed that those living in the most deprived areas of the country were significantly more likely to receive an APE than those living in the most affluent areas.

There were no obvious clinical reasons for these discrepancies, the findings showed.

APE may not only spell poorer quality of life for patients, but it is also more expensive, in terms of the maintenance costs of colostomies and the treatment of recurrent disease, say the authors.

"These problems must be addressed if the government is to attain its aims of ensuring a high quality of cancer care for all," they conclude.
-end-


BMJ

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.